Product Images Myrbetriq

Myrbetriq® (mirabegron extended-release tablets) is a medication taken once daily that comes in 25 mg tablets. The tablets should be swallowed whole and should not be crushed or chewed. This prescription medication is prescribed in 30-tablet quantities. All prescription medications, including Myrbetriq, should be kept out of reach of children.*

The text describes a chart that shows the effect of inhibitors/inducers of CYP3A/Pgp on PK fold change and 90% confidence interval. The chart includes recommended dose adjustments for ketoconazole and rifampicin, with no changes needed for these medications. The chart also includes solifenacin, tamsulosin, and metformin, with no dose adjustments recommended for these medications either. There is a graph as well, displaying the mean change relative to mirabegron alone over time.*

This text provides information on the recommended dose adjustments for various drugs that are metabolized by the enzymes CYP3A4 and CYP2D6. Solifenacin, ethinylestradiol, and levonorgestrel do not require any dose adjustment. Desipramine and metoprolol should be used with caution, while tamsulosin and metformin do not require any dose adjustment. Digoxin requires a starting dose adjustment, and for warfarin, the dosing should be guided by footnote 3. Information about the mean change relative to the substrate alone is also provided.*

This appears to be a table showing mean changes from baseline for different treatment groups in a clinical trial related to a drug called "mirabegron" at different time points. The drug was tested at two different doses: 25 mg and 50 mg. The table shows data for three groups: a placebo group (n=262), a group receiving mirabegron 25mg (n=254), and a group receiving mirabegron 50mg (n=257). However, without more context it is difficult to interpret the table further.*

This appears to be a table or graph displaying numerical data related to a study or clinical trial. It shows the mean change from baseline for participants receiving either a placebo or two doses of a drug called Mirabegron at 4, 8, and 12 weeks. However, without further context or explanation it is difficult to interpret the data or its significance.*

This text appears to be a chart depicting the adjusted change from baseline in some sort of study or experiment. The chart includes various measurements taken at different time periods (baseline, week 4, week 8, and week 12), and different dosages (25mg and 50mg). It's difficult to determine what exactly is being measured without more context, but it appears to be some sort of percent change in response to different treatments.*